Bone marrow failure
MPL-related congenital amegakaryocytic thrombocytopenia
MPL-related congenital amegakaryocytic thrombocytopenia is a genetic disorder that causes too few platelets and can progress to broader marrow failure. A donor stem-cell transplant can restore blood production. Confirming the genetic cause matters because similar-looking conditions may need different treatment.
Other names and abbreviations
CAMT · MPL-related congenital thrombocytopenia · thrombopoietin-receptor deficiency · bone marrow failure · Congenital amegakaryocytic thrombocytopenia type 1 · Congenital amegakaryocytic thrombocytopenia type 2
Where transplant fits
Allogeneic transplantation can correct blood production in MPL-related CAMT. A suitable unrelated donor is an established alternative when no appropriate matched sibling is available. It does not reverse injury caused by earlier bleeding.
Treatment depends on the exact diagnosis, disease stage, prior treatment and the person’s health. These categories are not estimates of donor demand.
What it is
Platelets help stop bleeding and are produced by marrow cells called megakaryocytes. In MPL-related CAMT, megakaryocytes are greatly reduced or absent and the platelet count is often very low from infancy.
The condition can later affect red and white cells as well. The pace varies with the genetic changes and remaining receptor function; an early platelet count does not by itself predict the entire course.
What causes it
MPL provides instructions for the receptor for thrombopoietin, a signal that supports platelets and blood-forming stem cells. Disease-causing changes in both copies can prevent cells from responding adequately to that signal.
Other causes of congenital low platelets can resemble CAMT. In particular, deficiency of the thrombopoietin signal itself, caused by THPO variants, is biologically different from MPL receptor deficiency. Treatment should follow the confirmed diagnosis.
What it can do
Bruising, pinpoint skin bleeding and other bleeding may appear around birth or later. Severe bleeding, including bleeding in the brain, is a possible complication but is not the experience of every child.
If wider marrow failure develops, anemia and infection risk can follow. Blood counts, marrow findings and clinical symptoms are monitored together to guide the timing of further treatment.
How it is treated
Platelet transfusions and other measures help control bleeding while diagnosis and longer-term care are arranged. Additional blood-product and infection support may be needed if other blood counts fall.
Allogeneic transplantation is the established definitive treatment for the blood-production defect in MPL-related CAMT. The transplant team weighs the disease course against graft failure, infection, conditioning toxicity and graft-versus-host disease.
A matching related or unrelated donor can be used. The choice of graft and conditioning depends on the child, the donor and center experience. Published outcomes from small or retrospective cohorts cannot guarantee an individual result.
Living with the condition
Families may be coordinating transfusions, diagnostic testing and transplant consultations for a very young child. Bleeding precautions and the plan for urgent symptoms should come from the treating team.
Transplant can prevent future consequences of failing blood production when successful. It does not reverse injury already caused by a major bleed, so some children also need developmental or rehabilitation support.
The donor’s role
An unrelated donor is an established option when a suitable sibling donor is unavailable. Related donors require specialist evaluation of their health and the familial genetic findings.
The donor supplies functioning blood-forming cells. That explanation applies to MPL-related CAMT; it must not be generalized to every infant with low platelets or every disorder described as congenital amegakaryocytic thrombocytopenia.
Treatment at a glance
- Who it affects
- Often recognized in infancy, although some MPL variants cause later or less severe presentation.
- Other treatment options
- Platelet transfusions and bleeding management provide support; red-cell and infection support may be needed if wider marrow failure develops.
- Cells used for transplantation
- Donor bone marrow is a common choice; other sources require protocol-specific assessment. Cord-blood experience does not establish equivalent graft-failure risk.
Why the details matter
This page concerns MPL receptor deficiency. THPO-related thrombopoietin deficiency and other causes of congenital thrombocytopenia have different treatment implications.
Questions to bring to your care team
What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?
Sources and further reading
- CAMT-MPL: heterogeneity of a monogenic disorder; analysis of 56 patients
Germeshausen and Ballmaier, Haematologica · 2021 - Fanconi Anemia and Other Hereditary Bone Marrow Failure Syndromes
EBMT Handbook · 2024-04-11
Understanding can become action.
Some patients need a blood stem cell donor. Others receive different treatment. Wherever your interest began, you can help JBF reach more people who may be able to donate.
Explore the official registry serving where you live. It explains who can join, how registration works and what donation involves.
Find your official registryIf joining is not right for you, a gift to the Jada Bascom Foundation supports education, outreach and referrals to official registries.
Donate to JBFKeep learning
Why matching is hard: an interactive leukemia story
More in bone marrow failure. Sharing a group does not mean sharing a treatment plan.
